NASDAQ:UBX - Unity Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.00
  • Forecasted Upside: 27.39 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.71
▼ -0.01 (-0.21%)
1 month | 3 months | 12 months
Get New Unity Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UBX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.00
▲ +27.39% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Unity Biotechnology in the last 3 months. The average price target is $6.00, with a high forecast of $12.00 and a low forecast of $4.00. The average price target represents a 27.39% upside from the last price of $4.71.

Hold

The current consensus among 6 contributing investment analysts is to hold stock in Unity Biotechnology. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021HC WainwrightInitiated CoverageBuy$12.00Low
i
Rating by A. Fein at HC Wainwright
3/26/2021MizuhoBoost Price TargetNeutral$4.00 ➝ $5.00High
i
2/16/2021CitigroupDowngradeNeutral ➝ Sell$5.00 ➝ $6.00Low
i
8/24/2020MizuhoReiterated RatingBuyHigh
i
Rating by Salim Syed at Mizuho
8/18/2020The Goldman Sachs GroupLower Price TargetNeutral$8.00 ➝ $4.00High
i
8/18/2020CitigroupDowngradeBuy ➝ Neutral$31.00 ➝ $5.00High
i
8/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$13.00 ➝ $5.00High
i
8/17/2020MizuhoDowngradeBuy ➝ Neutral$33.00 ➝ $4.00High
i
8/17/2020Roth CapitalDowngradeBuy ➝ Neutral$35.00 ➝ $4.00High
i
Rating by E. Pierce at Roth Capital
7/27/2020Roth CapitalInitiated CoverageBuy$35.00High
i
Rating by E. Pierce at Roth Capital
4/15/2020Morgan StanleyLower Price TargetOverweight$14.00 ➝ $13.00Low
i
12/12/2019Cantor FitzgeraldReiterated RatingOverweight$20.00High
i
Rating by B. Folkes at Cantor Fitzgerald
11/18/2019MizuhoReiterated RatingBuy$33.00Medium
i
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by B. Folkes at Cantor Fitzgerald
7/15/2019Morgan StanleySet Price TargetBuy$14.00Medium
i
Rating by Matthew Harrison at Morgan Stanley
3/6/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$21.00High
i
Rating by E. Piros at Cantor Fitzgerald
3/6/2019MizuhoReiterated RatingBuyHigh
i
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$25.00 ➝ $24.00High
i
9/6/2018MizuhoInitiated CoverageBuy ➝ Buy$33.00Medium
i
5/29/2018CitigroupInitiated CoverageBuy$32.00High
i
5/29/2018Morgan StanleyInitiated CoverageOverweight$25.00High
i
5/29/2018The Goldman Sachs GroupInitiated CoverageNeutral$17.00High
i
(Data available from 6/14/2016 forward)
Unity Biotechnology logo
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $4.71
$4.65
$4.84

50 Day Range

MA: $4.86
$4.20
$6.03

52 Week Range

Now: $4.71
$2.72
$15.44

Volume

562,335 shs

Average Volume

633,914 shs

Market Capitalization

$258.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Unity Biotechnology?

The following Wall Street analysts have issued stock ratings on Unity Biotechnology in the last twelve months: Citigroup Inc., HC Wainwright, Mizuho, Morgan Stanley, Roth Capital, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for UBX.

What is the current price target for Unity Biotechnology?

6 Wall Street analysts have set twelve-month price targets for Unity Biotechnology in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 27.4%. HC Wainwright has the highest price target set, predicting UBX will reach $12.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $4.00 for Unity Biotechnology in the next year.
View the latest price targets for UBX.

What is the current consensus analyst rating for Unity Biotechnology?

Unity Biotechnology currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in UBX, but not buy more shares or sell existing shares.
View the latest ratings for UBX.

What other companies compete with Unity Biotechnology?

How do I contact Unity Biotechnology's investor relations team?

The company's listed phone number is 650 416 1192. The official website for Unity Biotechnology is www.unitybiotechnology.com.